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REVIEW
Abstract: Noninvasive ventilation (NIV) has been one of the major advances in 
respiratory medicine in the last decade. NIV improves quality of life, prolongs survival, 
and improves gas exchange and sleep quality in restrictive patients, but evidence 
available now does not allow us to establish clear criteria for prescribing NIV in patients 
with chronic respiratory failure due to COPD. On the basis of the available studies, 
NIV should not be used as a treatment of choice for all patients with COPD, even when 
disease is severe. However, there is more evidence that NIV has an important effect in 
these patients. In fact, a selected group of patients may well benefit from domiciliary 
mechanical ventilation, and we need to be able to identify who they are. Moreover, NIV 
can be a new strategy to improve exercise tolerance in COPD patients.
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Introduction
Noninvasive ventilation (NIV) has been one of the major advances in respiratory 
medicine in the last decade. The 1990s can be considered the decade of NIV and 
home ventilation thanks to the important invention of the nasal mask (Díaz-Lobato 
and Mayoralas 2003). No doubt remains about the efﬁ  cacy of NIV in patients with 
chronic respiratory failure arising from thoracic restriction. Research has shown that 
NIV improves quality of life, prolongs survival, and improves gas exchange and 
sleep quality in restrictive patients (Lèger et al 1994; Mehta and Hill 2001; Nauffal 
et al 2002) (see also Tables 1 and 2). Debate continues, however, on the usefulness of 
long-term ventilation of COPD patients. Evidence available now does not allow us to 
establish clear criteria for prescribing NIV in patients with chronic respiratory failure 
due to COPD (Wedzicha and Muir 2002; Wijkistra et al 2002; Plant and Elliot 2003). 
Despite of lack of evidence for the effectiviness of NIV in COPD patients, this is one 
of the most common reasons for long-term home mechanical ventilation worldwide 
(Lloyd-Owen et al 2005).
Early uncontrolled studies on NIV in COPD patients, mainly using nasal masks, 
have shown that NIV is feasible at home in these patients, as had been previously found 
in chest wall and neuromuscular disease. During NIV, overnight abnormal physiology 
can be corrected, with improvements in gas exchange during sleep and sleep quality, 
exercise capacity, and diurnal arterial blood gas tensions (Elliot et al 1992; Krachman 
et al 1997; Sivasothy et al 1998; Costes et al 2003; Ambrosino and Strambi 2004). 
Use of health care resources may also be reduced and quality of life and functional 
score improved (Perrin et al 1997; Criner et al 1999; Hill 2004). Survival appears to 
be prolonged when the NIV outcomes are compared with those of the NOTT and 
MRC trials (Jones et al 1999).
However, there have been few controlled trials and these have had small numbers 
of patients followed over a short period of time (Strumpf et al 1991; Meecham-Jones 
Current status of noninvasive ventilation in stable 
COPD patients
Salvador Díaz-Lobato1
Sagrario Mayoralas Alises2
Esteban Pérez Rodríguez1
1Pneumological Department, Hospital 
Ramón y Cajal, Madrid, Spain;
2Hospital de Móstoles, Madrid, Spain
Correspondence: Salvador Díaz-Lobato
Federico García Lorca, 2, portal 7, 2A, 
28770-Colmenar Viejo,
Madrid, Spain.
Tel + 34 9133 68133
Email sdl01m@nacom.esInternational journal of COPD 2006:1(2)
Diaz-Lobato et al
130
et al 1995; Lin 1996). Only one study has shown any beneﬁ  t 
from the combination of NIV and long-term oxygen therapy 
(LTOT) in stable COPD patients (Meecham-Jones et al 1995). 
These authors reported a randomized crossover study of nasal 
pressure support ventilation plus oxygen therapy, compared 
with domiciliary oxygen therapy alone in 18 hypercapnic 
COPD patients. The aim of this study was to investigate the 
effect of the addition of NIV for patients already established on 
LTOT. Following a run-in period, each patient received NIV plus 
oxygen and oxygen alone in random order for 3-month periods. 
There was signiﬁ  cant improvement in daytime arterial blood 
gases, with the mean oxygen tension in arterial blood (PaO2) 
rising from 44.3 mmHg after the oxygen period to 50.2 mmHg 
after the addition of NIV and arterial carbon dioxide tension 
(PaCO2) falling from 57.0 mmHg to 52.5 mmHg. There were 
also improvements in overnight PaCO2, total sleep time, and 
sleep efﬁ  ciency, suggesting that control of hypoventilation in 
these patients was effective and leads to improved sleep quality. 
The improvement in daytime blood gas values was correlated 
with the change in overnight PaCO2, suggesting that the patients 
who showed the greatest improvement in PaCO2 with NIV were 
likely to gain the greatest beneﬁ  t from the treatment.
As noted above, this is the only study showing any beneﬁ  t 
from the combination of NIV and LTOT. There are a number 
of possible explanations for this, related to the way in which 
patients were acclimatized to NIV, the different hypercapnia 
levels between studies, and the differences in the type and 
settings of the ventilators.
Acclimatization to NIV
Patients were acclimatized to NIV in different ways. Strumpf 
et al (1991) performed a randomized crossover study of nasal 
ventilation using a bilevel device in 19 patients with COPD. 
Compliance proved to be a major problem in the study and 
only 7 patients completed both arms of the protocol; the poor 
compliance resulted mainly from problems with the nasal 
mask interface. In this study acclimatization was performed 
as an out patient, but with regular visits from a respiratory 
therapist. It is important to know that many patients do not 
ﬁ  nd NIV easy initially and in uncontrolled studies a higher 
success rate was achieved when patients started NIV in 
hospital under close supervision.
Another small study investigated the effects of the 
addition of NIV to oxygen therapy in severe COPD, but 
found no signiﬁ  cant beneﬁ  t of NIV after only 2 weeks of 
therapy (Lin 1996). Practical experience with both NIV and 
continuous positive airway pressure (CPAP) has suggested 
that most patients require several weeks of acclimatization 
before they are comfortable and conﬁ  dent with the delivery 
of ventilatory support during sleep. Therefore, a study time 
of 2 weeks was considered too short. In this study, patients 
had problems with higher levels of inspiratory positive airway 
pressure (IPAP  15 cm H2O) and this also suggests that 
they probably required a longer period of acclimatization 
to the ventilator.
When we are trying to facilitate a stable patient’s adapta-
tion to NIV, his or her comfort and tolerance of the technique 
is what should concern us in the initial stages. Once the 
patient has been adapted to the ventilator, the time comes 
to optimize ventilation. The long-term objectives of NIV 
are mainly to prolong survival, and improve quality of life 
and the functional status of the patient. Such achievements 
will not be feasible unless adaptation to the respirator and 
good tolerance have already been established, and that is 
why it becomes our principal aim. Only in few medical 
disciplines can we see such a direct relationship between 
adherence to treatment and success as we see in patients 
undergoing NIV (Mehta and Hill 2001; Díaz-Lobato 
Table 1 Guidelines for use of noninvasive ventilation in severe 
stable COPD
Symptomatic patient after optimal therapy
Sleep apnea excluded
PaCO2 >55 mmHg or
PaCO2 50–54 mmHg and evidence of nocturnal hypoventilation based on 
nocturnal oximetry showing sustained desaturation to < 89% for > 5 min 
while patient is on his or her usual FIO2
Repeated hospitalizations
Adapted from Consensus Conference (1999).
Table 2 Potential beneﬁ  ts of noninvasive ventilation in severe 
stable COPD
Can improve respiratory muscle strength in these patients
Increases in maximum inspiratory pressure
Improvement (or at least prevention of deterioration) in nocturnal and 
daytime gas exchange, and better quality-of-life scores
May increase walking distance, particularly if combined with 
rehabilitation
Prolongation of total sleep time in severely hypercapnic patients with 
some sleep-disordered breathing
Reduces the need for hospitalization
No convincing ﬁ  ndings demonstrate a favorable effect of NIV on 
survival, although a preliminary report of a controlled trial suggests 
beneﬁ  t in an older subgroup
From: Cropp and Dimarco (1987); Scano et al (1990); Leger et al (1994); 
Meecham-Jones et al (1995); Garrod et al (2000); Muir et al (2000); Clini et al 
(2002); Wijkstra et al (2003).International Journal of COPD 2006:1(2) 131
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and Mayoralas 2003). Criner et al (1999) have clearly 
established how a comprehensive follow up and support is 
necessary for all patients on home ventilation programs.
Hypercapnia levels
In the studies of Strumpf et al (1991) and Lin (1996), 
patients were not particularly hypercapnic (mean PaCO2 
46 mmHg and 50.5 mmHg respectively), whereas those in the 
study of Meecham-Jones et al (1995) had a mean PaCO2 of 
55.8 mmHg. In studies using negative pressure devices, any 
beneﬁ  ts observed have usually been in those with daytime 
hypercapnia (Braun 1984; Zibrak et al 1988; Celli et al 1989; 
Dubois 1990; Shapiro et al 1992).
Ventilator type and setting
The type and settings of the ventilators differed in reported 
studies. Meecham-Jones et al (1995) used pressure support 
ventilation with a mean IPAP of 18 cm H2O (Meechan-Jones 
et al 1995). Strumpf et al (1991) used a timed mode because 
it is more likely to reduce inspiratory muscle effort than 
patient-initiated ventilation, but noted that approximately 
25% of the night was spent with the patient breathing out 
of synchrony with the ventilator. Asynchrony between the 
patient and ventilator may cause worsening of gas exchange 
with both negative and positive pressure devices (Calderini 
et al 1999; Rabec et al 2004). The best synchrony between 
the patient and the respirator facilitates the reduction of work 
load for the diaphragm and increases the patient’s sense of 
well-being (see also Table 3).
Effective ventilation
It is important to conﬁ  rm that effective ventilation has 
been delivered before it can be concluded that NIV has 
no effect. The absence of these data does not allow us to 
know if failure in effectiveness is related to NIV itself or 
to optimal parameters not being chosen for performing 
NIV (Díaz-Lobato et al 2004). In the study of Strumpf 
et al (1991) carbon dioxide control during sleep was as-
sessed on the basis of spot measurements of end-tidal CO2 
monitoring (EtCO2) (Strumpf et al 1991). EtCO2 is an 
unreliable measure of PaCO2 in patients with severe air-
ways obstruction (Levine 2000). In the study of Lin (1996) 
no data were given about the effect of NIV on blood gas 
tensions during ventilation and there was no statistically 
signiﬁ  cant improvement in sleep hypoventilation with 
NIV. In the study of Gay et al (1996) CO2 tensions were 
not measured and there was no change in mean or nadir 
PaO2, during overnight polysomnography, which suggests 
that nocturnal hypoventilation was not controlled. By 
contrast Meecham-Jones et al (1995) showed a reduction 
in transcutaneous CO2 tension during sleep and this cor-
related with the improvement in daytime PaCO2 that was 
seen. Since a primary aim of NIV delivered during sleep is 
to control nocturnal hypoventilation, it can be argued that 
this was not achieved in the other studies and therefore a 
therapeutic effect with NIV cannot be afﬁ  rmed. It may also 
be signiﬁ  cant that Meecham-Jones et al (1995) used higher 
inﬂ  ation pressures (mean IPAP 18 cm H2O) than the other 
studies. Gay et al (1996) were the only group to compare 
active NIV with sham, and importantly two patients in the 
sham group reported that their breathing improved, despite 
unchanged results of the objective measures, suggesting a 
signiﬁ  cant placebo effect.
Two prospective, randomized, controlled trials including 
reasonable numbers of patients have been recently published 
(Casanova et al 2000; Clini et al 2002). In a 1-year controlled 
trial Casanova et al randomized 52 patients with severe stable 
COPD to either NIV plus “standard care” (96% patients 
with LTOT) or to standard care alone (93% patients with 
LTOT). The adequacy of ventilation was determined by 
close observation of the patient, during the day and night, 
but was not conﬁ  rmed objectively. One-year survival was 
similar in both groups (78%) as was the number of acute 
exacerbations. The number of hospital admissions was 
less at 3 months in the NIV group (5% vs 15%, p < 0.05), 
but this difference was not seen at 6 months (18% vs 19%, 
respectively). No statistically signiﬁ  cant differences in res-
piratory lung function or survival were found, although the 
authors did not analyze important variables such as quality 
of life or sleep. In this study the level of support was modest, 
Table 3 Monitoring noninvasive ventilation in COPD: basic 
aspects in a chronic setting
Patient comfort
Mask ﬁ  t and leak
Hours of use
Problems with adaptation (eg, nasal congestion, dryness, gastric 
insufﬂ  ation, conjunctival irritation, inability to sleep)
Symptoms (eg, dyspnea, fatigue, morning headache, hypersomnolence)
Gas exchange: daytime, nocturnal oximetry, blood gases measured 
periodically to assess PaCO2
Polysomnography if symptoms of sleep disturbance persist or nocturnal 
desaturation persists without clear explanationInternational journal of COPD 2006:1(2)
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mean IPAP 12±2 cm H2O. Ventilatory parameters should be 
selected considering changes of gas exchange parameters in 
response to night-time NIV together with effects seen dur-
ing the day. Thus, the poor results of the trial carried out by 
Casanova et al (2000) could simply be attributable to failure 
to achieve effective ventilation.
In the second study Clini et al (2002) undertook a 2-year, 
multicenter, prospective, randomized, controlled trial to 
assess the effect of NIV + LTOT on severity of hypercapnia, 
use of healthcare resources, and health-related quality of 
life (HRQL), in comparison with LTOT alone. One hun-
dred and twenty-two stable hypercapnic COPD patients 
on LTOT for more than 6 months were consecutively 
enrolled. After inclusion and 1-month run-in, 90 patients 
were randomly assigned to NIV + LTOT (n = 43) or to LTOT 
alone (n = 47). Arterial blood gases, hospital and intensive 
care unit (ICU) admissions, total hospital and ICU length 
of stay, and HRQL were primary outcome measures; 
survival and drop-out rates, symptoms (dyspnea and sleep 
quality), and exercise tolerance were secondary outcome 
measures. Follow-up was performed at 3-month intervals 
up to 2 years. In this study, compliance with LTOT was 
excellent and among NIV patients the mean night-time use 
of 9 hours compares very favorably with reported use in 
other studies. Lung function, inspiratory muscle function, 
exercise tolerance, and sleep quality score did not change 
over time in either group. By contrast the CO2 tension in 
arterial blood on usual oxygen, resting dyspnea and HRQL, 
changed differently over time in the two groups in favor 
of NIV + LTOT. Hospital admissions were not different 
between groups during the follow-up. Nevertheless, overall 
hospital admissions showed a different trend to change in 
the NIV + LTOT (decreasing by 45%) as compared with 
the LTOT group (increasing by 27%) when comparing the 
follow-up with the follow-back periods. ICU stay decreased 
over time by 75% and 20% in the NIV + LTOT and LTOT 
groups, respectively. Survival was similar. Compared with 
long-term oxygen therapy alone, the addition of noninvasive 
positive-pressure ventilation (NPPV) to long-term oxygen 
therapy in stable COPD patients with chronic ventilatory 
failure slightly decreased the trend to CO2 retention in 
patients receiving oxygen at home and improved dyspnea 
and HRQL (Clini et al 2002).
NIV was deemed to be adequate when the PaCO2 was 
reduced by 5% during wakefulness. We think this reduction in 
CO2 during NIV when awake is very modest. The changes in 
diurnal PaCO2 were small and it remains to be seen whether 
more aggressive ventilation would have resulted in a bigger 
change in this and other end points. The average IPAP was 
14 ± 3 cm and EPAP 2 ± 1 cm H2O, suggesting that there was 
room to increase the pressures, at least to levels closer to 
those seen in the study of Meecham-Jones et al (1995). 
End-expiratory pressure must be set to prevent rebreathing, 
to maintain alveoli open in patients with very low residual 
functional capacity and, particularly, in patients with COPD, 
to counterbalance intrinsic positive end-expiratory pressure. 
A low expiratory positive airway pressure (EPAP) could 
be responsible of certain degree of rebreathing and higher 
PaCO2 levels.
The fact that the effectiveness of ventilation during sleep 
was not conﬁ  rmed is an important limitation of the study 
and it is possible that there was in fact no change in PaCO2 
overnight, given that the pressures used were comparable 
with those used in the study of Lin (1996), in which no effect 
of NIV was seen upon sleep hypoventilation. If this is correct 
the question arises as to why patients reported less dyspnea 
and an improved quality of life.
Firstly, this could have been a placebo effect, as was 
seen in the study of Gay et al (1996). A signiﬁ  cant placebo 
effect has been seen with sham CPAP and the placebo effect 
of a “breathing machine” should not be underestimated 
(Jenkinson et al 1999).
Secondly, exacerbations have been shown to have a 
detrimental effect upon quality of life in patients with COPD 
(Seemungal et al 1998). NIV ofﬂ  oads the respiratory muscles 
and reduces the sensation of dyspnea associated with an acute 
exacerbation at ventilator settings similar to those used in 
this study (Bott et al 1993; Appendini et al 1994; Plant et al 
2000). It is possible that NIV therefore reduced the impact of 
exacerbations upon the patient; this may also have contributed 
to the trend towards reduced hospitalization. Compliance 
was considered to be acceptable if NIV use was greater than 
5 hours per day on average; in fact the mean daily use in those 
who achieved this minimum was much higher at 9 ± 2 hours 
per day. This suggests that at least some patients were using 
the ventilator during wakefulness, which lends some support 
to this hypothesis. Further data suggesting that NIV may be 
important in reducing the impact of exacerbations come from 
a small case series (Tuggey et al 2003), in which domiciliary 
NIV both reduced the frequency of hospitalization and was 
also economically advantageous. Patients who have received 
NIV in hospital for an acute exacerbation of COPD are at 
high risk for re-admission and death in the following year 
(Conti et al 2002; Chu et al 2004) and may be a particularly International Journal of COPD 2006:1(2) 133
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important group to target for chronic domiciliary NIV, though 
this needs to be evaluated in a prospective controlled trial 
(Elliot 2004).
Thirdly, no data are given about input from health care 
givers; this may affect quality of life and dyspnea (Cockcroft 
et al 1987). It is possible that patients receiving NIV, which 
requires considerable staff input at least initially, had greater 
contact with medical and paramedical staff than those on 
LTOT alone.
Two ﬁ  nal studies opening new research areas merit dis-
cussion (Schonhofer et al 1997; Díaz et al 2002). Schonhofer 
et al (1997) have shown that NIV can be equally effective 
when administered during the day or overnight during sleep. 
In this sense, Díaz et al (2002) have also shown that NIV 
administered during the day for 3 hours per day for 5 days 
in the week during wakefulness can improve arterial blood 
gases. This suggests that even relatively short periods of NIV 
can produce useful beneﬁ  t and for some patients, particularly 
those who cannot sleep with NIV this may be an attractive 
option. The “dose” of effective NIV may be relatively small. 
The primary aim of both of these studies was to investigate 
the mechanism by which NIV brings about improvement. 
There is no clear answer to this question but it is likely to be 
multifactorial, with different factors being more important in 
some patients than others. In this sense, respiratory muscle 
rest, restoration of chemosensitivity, improved compliance 
of the chest wall and lungs, improved sleep quality, and 
reduced respiratory system load would be factors to take 
into account.
Identifying COPD patients to NIV
So where do things now stand with regard to NIV in stable 
COPD? On the basis of the available studies, NIV should 
not be used as a treatment of choice for all patients with 
COPD, even when disease is severe (see Table 4). However, 
there is more evidence that NIV has an important effect in 
these patients. In fact, a selected group of patients may well 
beneﬁ  t from domiciliary mechanical ventilation, and we 
need to be able to identify who they are. Patients must have 
sustained hypercapnia, and control of nocturnal hypoventi-
lation with NIV must be conﬁ  rmed. A NIV trial should be 
initiated as an inpatient and patients should be motivated to 
comply with therapy and willing to be trained. The effect 
of NIV upon exacerbations and the amount of input from 
medical and paramedical staff should be quantiﬁ  ed. Sur-
vival must be included as an end-point, but quality, rather 
than prolongation, of life at any cost is more important to 
most patients with severe disability due to chronic disease. 
Finally, a detailed economic evaluation should be included. 
Such patients should be enrolled by researchers carrying out 
the next wave of randomized, controlled trials if we are to 
answer the question of whether to administer ventilation to 
patients with COPD. 
Until such a study is completed a trial of NPPV is 
recommended by the British Thoracic Society (BTS 2002) 
for COPD patients needing more than 7 days of NIV in the 
acute setting, for patients with severe hypercapnia even 
after adequate oxygenation, or for those who have been 
hospitalized 3 or more times in 1 year with hypercapnic 
respiratory failure. The 1999 Consensus Conference 
(Consensus Conference 1999), on the other hand, suggested 
that nocturnal ventilation be prescribed when PaCO2 is 
greater than 55 mmHg in the presence of hypoventilation 
symptoms. If PaCO2 falls to between 50 and 55 mmHg, the 
consensus was to recommend starting NIV if the patient had 
nocturnal desaturation deﬁ  ned as a pulse oximeter reading 
of less than 88% for longer than 5 consecutive minutes 
in spite of receiving oxygen at 2 L/min. Finally, along the 
lines of the BTS recommendations, night-time ventilatory 
support was considered appropriate for COPD patients 
with PaCO2 between 50 and 55 mmHg who had been 
hospitalized with hypercapnic respiratory insufﬁ  ciency at 
least twice in 1 year. Moreover, the Consensus Conference 
suggested also overlap syndrome as an indication of NIV 
in COPD patients. From a clinical perspective, the absence 
of clearly deﬁ  ned indications means that the use of NIV 
in stable COPD patients with hypercapnia tends to differ 
considerably from one group prescribing these techniques 
to another.
Finally, we would like to consider two new aspects of 
great interest concerning NIV in COPD patients. As we 
have seen before, perhaps the technique of NIV application 
Table 4 Relative contraindications to long-term noninvasive 
ventilation for COPD patients
Severe comorbidity that is likely to shorten survival more than lung 
disease (end-stage malignancy, liver disease). Congestive heart failure 
may respond favorably
Unmotivated patient
Nonadherence to oxygen or medical therapy
Cognitive impairment that interferes with patient’s ability to understand 
therapy
Insufﬁ  cient ﬁ  nancial resources
Insufﬁ  cient caregiver resources
Unable to tolerate or ﬁ  t mask, claustrophobic patientInternational journal of COPD 2006:1(2)
Diaz-Lobato et al
134
might be a major factor determining success of NIV 
treatment in patients with stable COPD. All published, 
randomized, controlled trials used either inspiratory 
pressures from 10 to 18 cm H2O or/and a spontaneous 
mode of ventilatory support for NIV that achieved only 
modest reductions in PaCO2 (Meecham-Jones et al 1995). 
There is increasing concern that inspiratory pressures of 
< 18  cm H2O might have been insufﬁ  cient to reduce the 
PaCO2 sufﬁ  ciently during spontaneous breathing in order 
to provide a clinical beneﬁ  t for the patient (Elliot 2002; 
Windisch et al 2002). However, there is increasing evi-
dence that chronic hypercapnia is a poor prognostic sign 
in patients with COPD. In addition, long-term survivors 
of patients with chronic respiratory failure due to COPD 
have been shown to have higher reductions in mean PaCO2 
during the ﬁ  rst 2 years following initiation of NIV (Leger 
et al 1994). Accordingly, indirect evidence supporting the 
hypothesis that more aggressive ventilation aimed at maxi-
mally decreasing PaCO2 could provide beneﬁ  cial effects for 
patients with stable hypercapnic COPD has been published 
(Leger et al 1994). Nevertheless, studies have not been 
undertaken to investigate this. Recently, controlled NIV 
using relatively high inspiratory pressures with a mean of 
28 cm H2O has been shown to signiﬁ  cantly improve lung 
function and blood gas levels during spontaneous breath-
ing in patients with stable hypercapnic COPD (Wendisch 
et al 2005). The high mean inspiratory pressure was well 
tolerated over a prolonged period by patients after careful 
adaptation to NIV in the hospital. These results suggests 
that further randomized controlled trials using NIV with 
higher inspiratory pressures are needed to verify the beneﬁ  ts 
of NPPV on outcome in these patients.
On the other hand, NIV has also been considered as a 
new strategy to improve exercise tolerance in COPD patients. 
It is known that NIV during exercise reduces dyspnea and 
work of breathing and enhances exercise tolerance in COPD 
patients. A systematic review identiﬁ  ed 15 physiological 
studies dealing with use of NIV during exercise (van’t Hul 
et al 2002). Seven of these studies met the inclusion criteria, 
including a total of 65 patients with COPD. The methodo-
logical quality of the included studies varied from 31%–54% 
of the maximum score of 13 points. Statistically signiﬁ  cant 
summary effect sizes were found in the analysis of exertional 
dyspnea as well as in the analysis of exercise endurance, 
indicating improvements in these outcomes in favor of NIV. 
Nevertheless, the role of NIV in pulmonary rehabilitation is 
still to be deﬁ  ned. 
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